Champions Oncology Inc reports results for the quarter ended April 30 - Earnings Summary

• Champions Oncology Inc CSBR.OQ reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended April 30, lower than the same quarter last year, when the company reported EPS of 1 cents. The lone analyst forecast for the quarter was for a loss of 20 cents per share.

• Revenue fell 11.8% to $12.36 million from a year ago; analysts expected $12.01 million.

• Champions Oncology Inc's reported EPS for the quarter was a loss of 13 cents​.

• The company reported a quarterly loss of $1.83 million.

• Champions Oncology Inc shares had risen by 5.2% this quarter and lost 9.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 35.4% above its last closing price of $7.75

This summary was machine generated from LSEG data July 24 at 04:56 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)